Lemborexant Patent Expiration
Lemborexant is Used for treating insomnia in adults with difficulties in sleep onset and/or sleep maintenance. It was first introduced by Eisai Inc
Lemborexant Patents
Given below is the list of patents protecting Lemborexant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dayvigo | US10188652 | Compositions and methods for treating insomnia | Oct 21, 2035 | Eisai Inc |
| Dayvigo | US10702529 | Compositions and methods for treating insomnia | Oct 21, 2035 | Eisai Inc |
| Dayvigo | US11026944 | Compositions and methods for treating insomnia | Oct 21, 2035 | Eisai Inc |
| Dayvigo | US8268848 | Cyclopropane compound | Sep 20, 2031 | Eisai Inc |
Lemborexant's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lemborexant:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. | Woolcock Institute of Medical Research | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic Surgery | Beijing Tiantan Hospital | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Lemborexant for Cannabis Use Disorder | University of Calgary | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| DORA and LP in Alzheimer's Disease Biomarkers | University of Minnesota | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial | Beijing Tiantan Hospital | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2 |
| The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold | Chulalongkorn University | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| The Effects of Lemborexant on the Ability to Sleep During Daytime | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | NA |
TERMINATED
(May 1, 2026)
| PHASE2 |